The New York Times reports:
The Pfizer-BioNTech coronavirus vaccine is extremely effective in adolescents 12 to 15 years old, perhaps even more so than in adults, the companies reported on Wednesday.
No infections were found among children who received the vaccine in a recent clinical trial, the drug makers said; the children produced strong antibody responses and experienced no serious side effects.
The findings, if they hold up, may speed a return to normalcy for millions of American families. Depending on regulatory approval, vaccinations could begin before the start of the next academic year for middle school and high school students, and for elementary school children not long after.
Read the full article.
Breaking News: A Pfizer-BioNTech trial found the vaccine extremely effective in 12- to 15-year-olds, with no coronavirus infections among children who received it.https://t.co/l37VNblWSE
— The New York Times (@nytimes) March 31, 2021